Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86


Two classes of anti-platelet drugs reduce anatomical infarct size in monkey hearts.

Yang XM, Liu Y, Cui L, Yang X, Liu Y, Tandon N, Kambayashi J, Downey JM, Cohen MV.

Cardiovasc Drugs Ther. 2013 Apr;27(2):109-15. doi: 10.1007/s10557-012-6436-7.


Platelet P2Y₁₂ blockers confer direct postconditioning-like protection in reperfused rabbit hearts.

Yang XM, Liu Y, Cui L, Yang X, Liu Y, Tandon N, Kambayashi J, Downey JM, Cohen MV.

J Cardiovasc Pharmacol Ther. 2013 May;18(3):251-62. doi: 10.1177/1074248412467692. Epub 2012 Dec 10.


Triple therapy greatly increases myocardial salvage during ischemia/reperfusion in the in situ rat heart.

Yang XM, Cui L, Alhammouri A, Downey JM, Cohen MV.

Cardiovasc Drugs Ther. 2013 Oct;27(5):403-12. doi: 10.1007/s10557-013-6474-9.


Mitochondrially targeted Endonuclease III has a powerful anti-infarct effect in an in vivo rat model of myocardial ischemia/reperfusion.

Yang XM, Cui L, White J, Kuck J, Ruchko MV, Wilson GL, Alexeyev M, Gillespie MN, Downey JM, Cohen MV.

Basic Res Cardiol. 2015 Mar;110(2):3. doi: 10.1007/s00395-014-0459-0. Epub 2015 Jan 17.


Cangrelor-Mediated Cardioprotection Requires Platelets and Sphingosine Phosphorylation.

Cohen MV, Yang XM, White J, Yellon DM, Bell RM, Downey JM.

Cardiovasc Drugs Ther. 2016 Apr;30(2):229-32. doi: 10.1007/s10557-015-6633-2.


Pharmacodynamic effects during the transition between cangrelor and ticagrelor.

Schneider DJ, Agarwal Z, Seecheran N, Keating FK, Gogo P.

JACC Cardiovasc Interv. 2014 Apr;7(4):435-42. doi: 10.1016/j.jcin.2013.08.017. Epub 2014 Mar 19.


Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.

Rollini F, Franchi F, Tello-Montoliu A, Patel R, Darlington A, Ferreiro JL, Cho JR, Muñiz-Lozano A, Desai B, Zenni MM, Guzman LA, Bass TA, Angiolillo DJ.

JACC Cardiovasc Interv. 2014 Apr;7(4):426-34. doi: 10.1016/j.jcin.2013.11.019. Epub 2014 Mar 13.


Pharmacodynamic effects during the transition between cangrelor and prasugrel.

Schneider DJ, Seecheran N, Raza SS, Keating FK, Gogo P.

Coron Artery Dis. 2015 Jan;26(1):42-8. doi: 10.1097/MCA.0000000000000158.


Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials.

Angiolillo DJ, Schneider DJ, Bhatt DL, French WJ, Price MJ, Saucedo JF, Shaburishvili T, Huber K, Prats J, Liu T, Harrington RA, Becker RC.

J Thromb Thrombolysis. 2012 Jul;34(1):44-55. doi: 10.1007/s11239-012-0737-3.


Combined cardioprotectant and antithrombotic actions of platelet P2Y12 receptor antagonists in acute coronary syndrome: just what the doctor ordered.

Cohen MV, Downey JM.

J Cardiovasc Pharmacol Ther. 2014 Mar;19(2):179-90. doi: 10.1177/1074248413508465. Epub 2013 Dec 2. Review.


Cangrelor: a novel intravenous antiplatelet agent with a questionable future.

Waite LH, Phan YL, Spinler SA.

Pharmacotherapy. 2014 Oct;34(10):1061-76. doi: 10.1002/phar.1471. Epub 2014 Aug 13. Review.


Blockade of the platelet P2Y12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model.

Wang K, Zhou X, Zhou Z, Tarakji K, Carneiro M, Penn MS, Murray D, Klein A, Humphries RG, Turner J, Thomas JD, Topol EJ, Lincoff AM.

Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):357-62.


Antagonism of P2Y12 or GPIIb/IIIa receptors reduces platelet-mediated myocardial injury after ischaemia and reperfusion in isolated rat hearts.

Barrabés JA, Inserte J, Mirabet M, Quiroga A, Hernando V, Figueras J, Garcia-Dorado D.

Thromb Haemost. 2010 Jul;104(1):128-35. doi: 10.1160/TH09-07-0440. Epub 2010 Apr 29.


Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring coronary artery bypass surgery.

Firstenberg MS, Dyke CM, Angiolillo DJ, Ramaiahm C, Price M, Brtko M, Welsby I, Chandna H, Holmes DR, Voeltz M, Tummala P, Hutyra M, Manoukian SV, Prats J, Todd M, Liu T, Chronos N, Dietrich M, Montalescot G, Cannon LA, Topo EJ.

Heart Surg Forum. 2013 Apr;16(2):E60-9. doi: 10.1532/HSF98.20121103.


Inhibition of Platelet GPVI Protects Against Myocardial Ischemia-Reperfusion Injury.

Pachel C, Mathes D, Arias-Loza AP, Heitzmann W, Nordbeck P, Deppermann C, Lorenz V, Hofmann U, Nieswandt B, Frantz S.

Arterioscler Thromb Vasc Biol. 2016 Apr;36(4):629-35. doi: 10.1161/ATVBAHA.115.305873. Epub 2016 Feb 25.


P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.

Iyú D, Glenn JR, White AE, Fox SC, Dovlatova N, Heptinstall S.

Platelets. 2011;22(7):504-15. doi: 10.3109/09537104.2011.576284. Epub 2011 May 19.


Transition strategies from cangrelor to oral platelet P2Y12 receptor antagonists.

Schneider DJ.

Coron Artery Dis. 2016 Jan;27(1):65-9. doi: 10.1097/MCA.0000000000000311. Review.


Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.

Golino P, Ambrosio G, Villari B, Ragni M, Focaccio A, Pace L, de Clerk F, Condorelli M, Chiariello M.

J Am Coll Cardiol. 1993 Feb;21(2):493-501.

Supplemental Content

Support Center